What is the chance that I will get an inhibitor?
The formation of inhibitors to FVIII is a known complication in the management of individuals with haemophilia A. In studies with recombinant FVIII products, development of inhibitors occurs predominantly in previously untreated patients. In a clinical trial of previously untreated patients taking KOGENATE® Bayer, 9 out of 60 (15%) developed inhibitors. In a clinical trial of previously treated patients using KOGENATE® Bayer 0 out of 72 (0%) developed inhibitors. However, inhibitors may occur at any time and can make your treatment less effective. Talk to your doctor if you feel your treatment is not working as well as it did previously as this could be a sign that an inhibitor is developing.
